A detailed history of Decheng Capital LLC transactions in Phathom Pharmaceuticals, Inc. stock. As of the latest transaction made, Decheng Capital LLC holds 1,250,000 shares of PHAT stock, worth $9.38 Million. This represents 5.35% of its overall portfolio holdings.

Number of Shares
1,250,000
Previous 850,000 47.06%
Holding current value
$9.38 Million
Previous $8.76 Billion 158.14%
% of portfolio
5.35%
Previous 2.68%

Shares

2 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$10.25 - $19.5 $4.1 Million - $7.8 Million
400,000 Added 47.06%
1,250,000 $22.6 Billion
Q4 2023

Feb 12, 2024

BUY
$6.99 - $10.71 $5.94 Million - $9.1 Million
850,000 New
850,000 $7.76 Billion

Others Institutions Holding PHAT

About Phathom Pharmaceuticals, Inc.


  • Ticker PHAT
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 39,175,200
  • Market Cap $294M
  • Description
  • Phathom Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases. The company has the rights in the United States, Europe, and Canada to vonoprazan, a potassium-competitive acid blocker (P-CAB) that blocks acid secretion in the stomach. It is also develo...
More about PHAT
Track This Portfolio

Track Decheng Capital LLC Portfolio

Follow Decheng Capital LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Decheng Capital LLC, based on Form 13F filings with the SEC.

News

Stay updated on Decheng Capital LLC with notifications on news.